Business
Notice of Preliminary Results
Notice of Preliminary Results.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 8147R Futura Medical PLC 05 March 2019 \n\n \nNotice of Preliminary Results\n05 March 2019\nFutura Medical plc (AIM: FUM) (the \"Company\"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, will announce its preliminary results for the year ended 31 December 2018 on Wednesday 10 April 2019.\nJames Barder, Chief Executive Officer, and Angela Hildreth, Finance Director/Chief Operating Officer, will host a presentation for analysts at 10am BST on the day of the results at the office of N+1 Singer at 1 Bartholomew Lane, London EC2N 2AX.\nA copy of the announcement will be made available on the Futura Medical website and following the results meeting a webcast of the presentation to analysts will also be made available within the Investor Centre section of the site.\nFor further information please contact:\nFutura Medical plc \nJames Barder, Chief Executive\nAngela Hildreth, Finance Director and COO\nEmail: [email protected]\nTel: +44 (0) 1483 685 670\n \nNominated Adviser and Broker:\nN+1 Singer\nAubrey Powell/ Ben Farrow (Corporate Finance)\nMia Gardner/ Tom Salvesen (Corporate Broking)\nTel: +44 (0) 20 7496 3000\n \nFor media enquiries please contact:\nOptimum Strategic Communications\nMary Clark/ Hollie Vile/ Ellie Blackwell\nEmail: [email protected]\nTel: +44 (0) 203 950 9144\n \nNotes to editors:\nAbout Futura Medical plc\nFutura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.\n \nFutura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com\n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act...